Sign Out
Lipo-Dox, as a monotherapy, is indicated for the treatment of metastatic breast cancer.
Lipo-Dox is indicated for the treatment of advanced ovarian cancer in women who have failed a first-line platinum based chemotherapy regimen. Lipo-Dox is also indicated for AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.
Lipo-Dox may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracyclines).
Lipo-Dox is indicated in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or unsuitable for bone marrow transplant.
